Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Article Type
Close
Date
Availability
1-20 of 188
Breaking
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
News
Publisher: American Association for Cancer Research
Published: 09 February 2025
Abstract
The NIH announced it will immediately reduce its support for indirect costs of research accrued by grant-recipients. Also known as facilities and administration costs, indirect costs include utilities, maintenance, personnel, and other expenses not directly related to scientific projects. The NIH funds indirect costs as an additional percentage of its grants, a sum negotiated with each university or research institution; $9 billion went to these costs in 2023. Indirect costs associated with all NIH grants will be limited to 15%, down from an average rate of 27% to 28%, a change projected to save the government $4 billion a year. The guidance document also noted that private foundations almost never cover more than 15% indirect costs—and that the rate is often 0%.
News
Publisher: American Association for Cancer Research
Published: 07 February 2025
Abstract
A bipartisan group of senators reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act , which would expand Medicare coverage to include certain FDA-approved MCED tests, blood tests that simultaneously screen for biomarkers of multiple cancer types. Coverage will not begin until 2028, according to the bill, at which point individuals ages 68 and younger will be covered. Each subsequent year, coverage will increase by one year; in 2029, for example, individuals ages 69 and younger will be covered. The bill received overwhelming support at the committee level in the previous Congress but was not voted on before the current Congress took office.
News
Publisher: American Association for Cancer Research
Published: 05 February 2025
Abstract
The UK’s National Health Service will enroll nearly 700,000 women in a trial to study how artificial intelligence (AI) tools can aid in the diagnosis of breast cancer. In the EDITH trial, supported by £11 million (about $13.8 million) from the UK’s National Institute for Health Care and Research, women ages 50 to 71 will be screened every 3 years at one of 30 sites across the UK. Five distinct AI platforms will be used to analyze and diagnose about two thirds of the mammograms, which will be compared to the remaining one third of scans to be analyzed by two specialists, the current standard for mammograms in the UK. A recent study involving more than 460,000 women found that radiologists identified nearly 18% more breast tumors on mammograms when using AI assistance ( Cancer Discov 2025 Feb 4 [Epub] ), but no studies have yet investigated how AI fares in diagnosing breast cancer on its own in a population as large as EDITH’s.
News
Publisher: American Association for Cancer Research
Published: 04 February 2025
Abstract
The Senate Finance Committee voted today in favor of Robert F. Kennedy (RFK) Jr.’s nomination for Secretary of the Department of Health and Human Services, setting up a Senate floor vote. While the 13 Democrats on the committee voted no, all the committee’s 14 Republicans voted to advance the nomination, including Bill Cassidy, MD (R-La.), a physician who implored RFK Jr. during last week’s hearing––to no avail––to reject theories that vaccines cause autism and said he was “struggling” with the nomination. Cassidy today wrote on X that “with the serious commitments I’ve received from the administration and the opportunity to make progress on the issues we agree on like healthy foods and a pro-American agenda, I will vote yes.” The full Senate is expected to vote within the next week.
News
Publisher: American Association for Cancer Research
Published: 03 February 2025
Abstract
The U.S. National Science Foundation (NSF) announced that payments have been restored to the researchers who receive funding from the independent federal agency. Grant-recipients’ salaries were suspended last week amid the Trump administration’s federal funding freeze on grants and federal loans. Subsequently, a federal court issued an order preventing federal grant-issuing agencies, including the NSF, from withholding awards.
News
Publisher: American Association for Cancer Research
Published: 31 January 2025
Abstract
The U.S. National Science Foundation’s (NSF) payment system remains offline following the Trump administration’s federal funding freeze on grants and federal loans issued earlier this week, according to STAT . This comes despite a judge blocking the freeze before it could take effect and the Trump administration rescinding the memo that announced the freeze the following day. An independent federal agency, the NSF spends its $9 billion-a-year budget funding research across the sciences, and many researchers depend on NSF grants and fellowships to pay their salaries. The NSF is “working expeditiously to conduct a comprehensive review of our projects, programs, and activities to be compliant with the existing executive orders,” according to a statement on its website, likely referring to President Donald Trump’s orders rolling back diversity, equity, and inclusion initiatives in federal programs and prohibiting the use of federal funds to promote “gender ideology.”
News
Publisher: American Association for Cancer Research
Published: 30 January 2025
Abstract
At today’s Senate Health, Education, Labor, and Pensions Committee hearing, nominee for Secretary of the Department of Health and Human Services Robert F. Kennedy (RFK) Jr. refused to renounce his claims that the human papillomavirus (HPV) vaccine is “dangerous and defective.” When given the opportunity to do so, Kennedy instead pointed to an ongoing lawsuit involving Merck and claims the company didn’t adequately disclose the side effects of Gardasil, its HPV vaccine; Kennedy litigated the case at earlier stages and stands to profit if Merck loses. According to the U.S. Centers for Disease Control and Prevention, HPV infection causes nearly all cases of cervical cancer, and more than 90% of HPV-caused cancers––which also include some anal, penile, vulvar, vaginal, and head and neck cancers—can be prevented through vaccination.
News
Publisher: American Association for Cancer Research
Published: 30 January 2025
Abstract
Cargo Therapeutics discontinued a study evaluating firicabtagene autoleucel , an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma and the company’s lead candidate; it was being tested in patients whose disease was relapsed or refractory to CD19 CAR T-cell therapy. The decision comes on the heels of an ad hoc analysis of the phase II FIRCE-1 study, in which 18% of 51 patients developed immune effector cell–associated hemophagocytic lymphohistiocytosis-like syndrome––a hyperinflammatory toxicity associated with some CAR T-cell therapies––including grade 4 and 5 adverse events. Additionally, although 43% of patients had a complete response, only 18% maintained the response after 3 months.
News
Publisher: American Association for Cancer Research
Published: 29 January 2025
Abstract
Following public protest and a political firestorm, the Trump administration nixed an executive order calling for federal grants and loans to be frozen . The order, issued late Monday by the Office of Management and Budget (OMB), was to go into effect at 5 pm Eastern time yesterday, but a federal judge halted it after a lawsuit was filed. A two-sentence memo issued this afternoon by OMB Acting Director Matthew Vaeth reversed the original order: “OMB Memorandum M-25-13 is rescinded. If you have questions about implementing the President’s Executive Orders, please contact your agency General Counsel.” No other information was released.
News
Publisher: American Association for Cancer Research
Published: 29 January 2025
Abstract
Shortly before funding for federal loans and grants was set to be frozen on January 28, a federal judge in the District of Columbia issued a temporary stay. The New York Times reported that the decision came in response to a lawsuit filed by Democracy Forward, which that argued the Trump administration was overstepping its legal authority by freezing federal monies. The stay will last until at least February 3, when the judge will hold a hearing on the matter. Separately, attorneys general from 22 states and the District of Columbia filed a similar lawsuit. Although the acting director of the NIH has said that current clinical trials could continue despite the funding freeze, new grants and research projects would be unable to start; the fate of other federally supported cancer-related research and treatment programs remains unclear.
News
Publisher: American Association for Cancer Research
Published: 28 January 2025
Abstract
The Daiichi Sankyo/Astra Zeneca antibody–drug conjugate trastuzumab deruxtecan (Enhertu; T-DXd) was approved by the FDA for HER2-low and ultralow metastatic breast cancer . The decision was based on results from the phase III DESTINY-Breast06 trial, in which patients taking the HER2-targeting agent had a 36% lower risk of disease progression or death compared with those who received chemotherapy. The median progression-free survival was 13.2 months in the T-DXd group and 8.1 months in the chemotherapy group; objective response rates were 63% and 34%, respectively. T-DXd is now approved for seven indications, the first of which was the 2019 approval for inoperable HER2-positive breast cancer.
News
Publisher: American Association for Cancer Research
Published: 28 January 2025
Abstract
The Trump administration directed federal agencies to temporarily pause grants and payments of federal funds in a memo released late yesterday by Matthew Vaeth, the acting director of the Office of Management and Budget. No end date was provided for the pause, which goes into effect today at 5 p.m. Eastern time. According to the memo, the pause “will provide the Administration time to review agency programs and determine the best uses of the funding for those programs consistent with the law and the President’s priorities.” Agencies were also called upon to ensure their grant and loan programs are compliant with President Trump’s executive orders, which call for the end of diversity, equity, and inclusion initiatives in the federal government and the withdrawal of the United States from the World Health Organization, among other actions. The extent to which the funding freeze will affect cancer-related research grants remains unclear. However, the acting director of the NIH, Matthew Memoli, MD, MS, subsequently said that current clinical trials could continue but that no new research could begin.
News
Publisher: American Association for Cancer Research
Published: 26 January 2025
Abstract
The webpage for Project Equity has been pulled from the FDA website, seemingly in response to the Trump administration’s halt of diversity, equity, and inclusion (DEI) initiatives, NPR has reported. The program was launched in 2021 by the agency’s Oncology Center of Excellence to help ensure that people enrolled in clinical trials of cancer drugs reflect the population of patients for whom the medicines are intended. To that end, Project Equity encouraged researchers to consider a variety of factors—race, ethnicity, sex, age, socioeconomic status, and geographic location, among others—when enrolling patients in clinical trials. Although a draft guidance for industry on creating diversity action plans for clinical trials, issued last June, had also been taken down, online access to it has been restored.
News
Publisher: American Association for Cancer Research
Published: 24 January 2025
Abstract
The Trump Administration has withdrawn a proposed rule that would’ve banned menthol cigarettes and flavored cigars—even though all other flavorings have already been prohibited. The FDA proposed the rule in 2022 to help prevent young people, who are attracted to flavorings, from starting smoking. Menthol cigarettes are also preferred in Black communities, which see disproportionately higher rates of smoking and smoking-related health problems. The rule was sent to the White House in October 2023 for a final OK, but the Biden Administration never advanced it after meeting with groups opposing it. Tobacco companies argued that the ban would cause them to lose billions in revenue annually.
News
Publisher: American Association for Cancer Research
Published: 23 January 2025
Abstract
The Trump administration abruptly cancelled NIH grant-review panel meetings , along with NIH travel and hiring, after all federal health officials were ordered to freeze public communications. The panels, also known as study sections, meet to review research grant proposals and award grants––which account for 80% of the agency’s $47 billion budget and support research at more than 2,500 institutions––but researchers reported that meetings were cancelled without warning, preventing the distribution of research grants. The federal memo announcing the communications freeze said it would lift on February 1, but no end date was given for the cancellation of study section meetings.
News
Publisher: American Association for Cancer Research
Published: 22 January 2025
Abstract
U.S. Department of Health and Human Services (DHHS) employees were ordered to halt all external communications in a memo sent today by acting DHHS Secretary Dorothy Fink, MD, to the heads of all federal health agencies. The freeze applies to health advisories, weekly scientific reports, updates to websites, and social media posts from the FDA, Centers for Disease Control and Prevention (CDC), the NIH, and the other 10 agencies that operate under DHHS, according to The Washington Post . The memo stated that the freeze applies until February 1 and that some exceptions would be made for communications affecting "critical health, safety, environmental, financial or nation security functions," although these would be subject to review, according to NPR . The action is "consistent with precedent," according to the memo, but no other reason was given.
News
Publisher: American Association for Cancer Research
Published: 18 January 2025
Abstract
Three cancer drugs separately earned FDA approval :
The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with metastatic colorectal cancer with a KRAS G12C mutation. Regulators based their decision on results of the phase III CodeBreaK 300 trial in which progression-free survival (PFS) was 5.6 months for those who received the combination versus 2 months for those who received investigator’s choice standard trifluridine/tipiracil or regorafenib (Stivarga; Bayer).
The Bruton tyrosine kinase inhibitor acalabrutinib (Calquence; AstraZeneca) was approved for use with bendamustine and the anti-CD20 mAb rituximab (BR) to treat adults newly diagnosed with mantle cell lymphoma (MCL). In the phase III ECHO trial, that combination led to a 32% improvement in PFS over a placebo plus BR, but it elicited serious adverse reactions in 69% of patients.
Regulators also greenlighted datopotamab deruxtecan (Datroway; Daiichi Sankyo) for adults with inoperable, metastatic HR-positive, HER2 - negative breast cancer who’ve already received an endrocrine-based therapy and chemotherapy. The TROP2-directed antibody–drug conjugate improved PFS by 2 months over investigator’s choice of chemotherapy but yielded no significant improvement in overall survival.
News
Publisher: American Association for Cancer Research
Published: 17 January 2025
Abstract
NCI Director W. Kimryn Rathmell, MD, PhD, announced today that she will step down effective Monday, January 20, the same day Donald Trump will be inaugurated as president. Rathmell, who had previously served as chair of the Department of Medicine at Vanderbilt University in Nashville, TN, began her NCI tenure in December 2023. Additionally, today is Monica Bertagnolli, MD’s, final day as the NIH director, a role she has held since November 2023. Bertagnolli preceded Rathmell as NCI director, prior to which she was a surgeon at Brigham and Women’s Hospital in Boston, MA.
News
Publisher: American Association for Cancer Research
Published: 16 January 2025
Abstract
Although it has risen from 7% over the past decade, the relative 5-year survival rate for pancreatic cancer is 13% , the same rate as reported last year, according to the just released American Cancer Society’s Cancer Facts & Figures, 2025 report. Patients with pancreatic adenocarcinoma, the most common form of the disease, have just an 8% 5-year survival rate. About 67,440 Americans will be diagnosed with pancreatic cancer this year, and 51,980 are predicted to die from it.
News
Publisher: American Association for Cancer Research
Published: 15 January 2025
Abstract
The FDA will prohibit the use of the red food dye FD&C Red No. 3 , also known as erythrosine or Red 3, in foods and ingested drugs. The decision comes in response to a 2022 petition asking the agency to review whether the dye should be banned under the Delaney Clause, which prohibits FDA authorization of a food or color additive found to cause cancer in humans or animals. Studies have shown that exposure to high levels of Red No. 3 causes cancer in rats, although rats have a specific hormonal mechanism not present in humans. Manufacturers who use Red No. 3 in food and ingested drugs will have until January 15, 2027, or January 18, 2028, respectively, to reformulate their products.
1